Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
VYGR: A holder filed a Form 144 notice to sell 7,666 shares of common stock. The filing lists an aggregate market value of $36,633.51 and an approximate sale date of 10/03/2025, with sales through Fidelity Brokerage Services LLC on NASDAQ.
The shares were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 55,468,806; this is a baseline figure, not the amount being sold.
Voyager Therapeutics, Inc. furnished an investor presentation in connection with its appearance at Citi’s 2025 Biopharma Back to School Conference. The company plans to present the materials in Exhibit 99.1 on September 2, 2025 at 4:00 p.m. ET.
The presentation is being provided under Regulation FD and, along with Item 7.01, is treated as “furnished” rather than “filed,” which limits certain securities law liabilities and incorporation by reference. Voyager states it is not admitting the materiality of the information and notes that these materials should be read together with its other SEC filings and public disclosures, and it does not undertake an obligation to update them.
Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported the sale of 19,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $3.73 per share. After the reported sale, Mr. Ferguson beneficially owned 138,914 shares, held directly. The filing discloses that the $3.73 figure is a weighted average for multiple transactions executed at prices ranging from $3.69 to $3.79 and states the reporting person will provide a detailed breakdown of shares sold at each price on request. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Voyager Therapeutics, Inc. (VYGR) filed a Form 144 notifying a proposed sale of 19,000 common shares that vested as restricted stock on 04/01/2025. The shares are held at Fidelity Brokerage Services and were acquired as compensation. The filer estimates an aggregate market value of $70,680 and reports 55,468,806 shares outstanding; the approximate sale date is 08/18/2025 on NASDAQ. The filer reports no sales in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 4,800,000 shares of Voyager Therapeutics, Inc. common stock, representing 8.65% of the outstanding shares based on 55,468,806 shares outstanding. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and that Armistice exercises shared voting and dispositive power over the reported shares. Neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the holder with the right to receive proceeds or dividends.